Afexa Life Sciences Inc (FXA.TO), maker of Cold-FX, Canada's most popular over-the-counter flu medicine, is optimistic it can find a white knight to block a hostile takeover bid by Paladin Labs (PLB.TO). Afexa Chairman Bill White told Reuters in an interview on Wednesday that the company has held talks with several interested parties, but declined to be more specific. "We've had really good success in terms of people who we have reached out to as well as incoming interest," White said by telephone. "We're aggressively pursuing these alternatives and believe that we'll be able to bring something to shareholders that allows them to see the Paladin offer in the light that we do as well as other opportunities to maximize value." Paladin is offering 55 Canadian cents a share or 0.013 of a Paladin share for each Afexa share it does not already own, valuing the company at C$56.7 million ($57.3 million).
Source
